168 related articles for article (PubMed ID: 31810928)
21. Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Zhitao J; Long L; Jia L; Yunchao B; Anhua W
Tumour Biol; 2015 Dec; 36(12):9621-30. PubMed ID: 26142735
[TBL] [Abstract][Full Text] [Related]
22. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; Ahnert P; Meixensberger J; Walczak H
Clin Cancer Res; 2007 Jun; 13(11):3403-12. PubMed ID: 17545549
[TBL] [Abstract][Full Text] [Related]
24. Autophagy-Mediated Degradation of IAPs and c-FLIP(L) Potentiates Apoptosis Induced by Combination of TRAIL and Chal-24.
Xu J; Xu X; Shi S; Wang Q; Saxton B; He W; Gou X; Jang JH; Nyunoya T; Wang X; Xing C; Zhang L; Lin Y
J Cell Biochem; 2016 May; 117(5):1136-44. PubMed ID: 26448608
[TBL] [Abstract][Full Text] [Related]
25. Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas.
Giaisi M; Köhler R; Fulda S; Krammer PH; Li-Weber M
Int J Cancer; 2012 Aug; 131(4):1003-8. PubMed ID: 21952919
[TBL] [Abstract][Full Text] [Related]
26. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
27. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis.
Siegelin MD; Siegelin Y; Habel A; Gaiser T
Neurosci Lett; 2009 Apr; 453(2):92-7. PubMed ID: 19356600
[TBL] [Abstract][Full Text] [Related]
28. The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP.
Um HJ; Oh JH; Kim YN; Choi YH; Kim SH; Park JW; Kwon TK
Chem Biol Interact; 2010 Jun; 186(1):36-42. PubMed ID: 20403343
[TBL] [Abstract][Full Text] [Related]
29. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
30. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
Kang J; Bu J; Hao Y; Chen F
Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
[TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of celecoxib in tumor necrosis factor‑related apoptosis‑inducing ligand treatment in osteosarcoma cells.
Liu G; Yu MY; Huang X; Zhu D; Cheng S; Ma R; Gu G
Mol Med Rep; 2014 Oct; 10(4):2198-202. PubMed ID: 25050836
[TBL] [Abstract][Full Text] [Related]
32. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
33. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
34. Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins.
Yang L; Wang Q; Li D; Zhou Y; Zheng X; Sun H; Yan J; Zhang L; Lin Y; Wang X
Apoptosis; 2013 May; 18(5):618-26. PubMed ID: 23371323
[TBL] [Abstract][Full Text] [Related]
35. Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways.
van Dijk M; Halpin-McCormick A; Sessler T; Samali A; Szegezdi E
Cell Death Dis; 2013 Jul; 4(7):e702. PubMed ID: 23828565
[TBL] [Abstract][Full Text] [Related]
36. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
[TBL] [Abstract][Full Text] [Related]
37. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
[TBL] [Abstract][Full Text] [Related]
38. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis.
Murphy ÁC; Weyhenmeyer B; Noonan J; Kilbride SM; Schimansky S; Loh KP; Kögel D; Letai AG; Prehn JH; Murphy BM
Apoptosis; 2014 Apr; 19(4):629-42. PubMed ID: 24213561
[TBL] [Abstract][Full Text] [Related]
39. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals.
Seal S; Hockenbery DM; Spaulding EY; Kiem HP; Abbassi N; Deeg HJ
Exp Hematol; 2008 Dec; 36(12):1660-72. PubMed ID: 18838202
[TBL] [Abstract][Full Text] [Related]
40. Role of IG20 splice variants in TRAIL resistance.
Prabhakar BS; Mulherkar N; Prasad KV
Clin Cancer Res; 2008 Jan; 14(2):347-51. PubMed ID: 18223207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
